Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They ...
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright initiated coverage of Veritone (VERI) with a Buy rating and $6 price target Veritone designs, develops, and distributes ...
Hosted on MSN17d
H.C. Wainwright maintains Buy on Altimmune stock, $12 targetO n Thursday, H.C. Wainwright reaffirmed a positive stance on Altimmune (NASDAQ:ALT) shares, maintaining a Buy rating and a $12.00 price target. Currently trading at $6.99 with a market ...
Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...
will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...
Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...
In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback